- ByInvesting.com-
Investing.com -- Novo Nordisk A/S has reduced the listing prices of its obesity drug Wegovy by half in some Chinese provinces,...
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 318.6 | 318.8 | 315.1 | +2.8 | +0.89% | 1.04M | ||
| 835.2 | 837.8 | 829.0 | +2.6 | +0.31% | 136.93K | ||
| 1,615.0 | 1,620.5 | 1,597.0 | +1.0 | +0.06% | 217.98K | ||
| 325.3 | 329.0 | 324.3 | -2.5 | -0.76% | 3.85M | ||
| 14,640 | 14,695 | 14,500 | +35 | +0.24% | 10.19K | ||
| 407.8 | 409.2 | 405.4 | +1.1 | +0.27% | 303.49K | ||
| 14,640 | 14,700 | 14,510 | +10 | +0.07% | 3.02K | ||
| 798.5 | 798.5 | 785.0 | +8.5 | +1.08% | 82.96K | ||
| 2,027.0 | 2,053.0 | 2,012.0 | -53.0 | -2.55% | 148.82K | ||
| 445.0 | 446.2 | 439.2 | +2.8 | +0.63% | 63.79K | ||
| 173.4 | 174.0 | 168.9 | +2.5 | +1.46% | 1.44M | ||
| 215.2 | 215.4 | 212.6 | 0.0 | 0.00% | 199.85K | ||
| 166.5 | 166.8 | 165.5 | +0.7 | +0.42% | 338.83K | ||
| 546.4 | 547.2 | 541.0 | +2.4 | +0.44% | 228.21K | ||
| 872.5 | 874.0 | 860.0 | +10.5 | +1.22% | 103.12K | ||
| 707.6 | 707.6 | 695.0 | +4.2 | +0.60% | 196.8K | ||
| 225 | 225 | 223 | +1 | +0.45% | 137.68K | ||
| 466.40 | 483.10 | 463.70 | -17.30 | -3.58% | 385.67K | ||
| 217.20 | 218.00 | 215.60 | +1.20 | +0.56% | 226.19K | ||
| 122.35 | 122.35 | 120.00 | -0.20 | -0.16% | 1.48M |
Investing.com -- Novo Nordisk A/S has reduced the listing prices of its obesity drug Wegovy by half in some Chinese provinces,...
Investing.com -- Orsted A/S has agreed to sell a 55% stake in its Greater Changhua 2 offshore wind farm to Taiwanese firm Cathay...
Investing.com -- Shares in Novo Nordisk (CSE:NOVOb) jumped more than 8% on Tuesday after the company won U.S. approval for its...
It’s no secret that the Trump administration is skeptical, to put it mildly, of alternative energy. If that was a signal for...
Novo Nordisk A/S (NYSE:NVO) announced that CEO Lars Fruergaard Jørgensen is stepping down amid mounting challenges, with...
Rate cuts are on the horizon—discover which sectors are poised to benefit. Defensive stocks could thrive as lower interest rates...
No Earning Reports have been scheduled